

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Maria Del Castillo,¹ Fabian A. Romero,² Esther Argüello,² Chrisann Kyi,³ Michael A. Postow,² and Gil Redelman-Sidi²

¹Department of Medicine, Jacobi Medical Center, Bronx; ²Department of Medicine, Memorial Sloan Kettering Cancer Center, and ³Department of Medicine, Icahn School of Medicine at Mount Sinai, New York

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

Keywords. infection; melanoma; checkpoint blockade; immunotherapy.

In the last decade, the development of immune checkpoint-blocking antibodies, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1), and programmed death ligand 1 (PD-L1), has ushered in great promise in the treatment of melanoma and other cancers [1–9]. Several checkpoint inhibitors are now approved by the US Food and Drug Administration for the treatment of melanoma (ie, the CTLA-4 blocking antibody [ipilimumab, Bristol-Myers Squibb], PD-1 blocking antibodies [pembrolizumab, Merck; nivolumab, Bristol-Myers Squibb], and, most recently, the combination of nivolumab plus ipilimumab [1, 2, 10]), and preclinical and clinical data now support the use of these drugs in a rapidly expanding spectrum of malignancies.

Use of immune checkpoint-blocking drugs is associated with a constellation of unique immune-related adverse effects (irAEs) related to the upregulated immune system. These toxicities affect a variety of organ systems including skin (rash), gastrointestinal tract (colitis), pancreas (pancreatitis), liver (hepatitis), endocrine (hypophysitis, thyroiditis), lung (pneumonitis), and kidneys

(nephritis) [11, 12]. Immune-related adverse effects are generally reversible when managed according to standard algorithms that make use of immunosuppressive medications such as steroids or, if refractory, tumor necrosis factor alpha (TNF- α) inhibitors (infliximab) [11, 13–15].

Preclinical studies have raised concerns that immune checkpoint blockade is directly associated with increased susceptibility to certain infections, including tuberculosis [16] and listeriosis [17, 18]. A second concern is that susceptibility to infection could increase due to immunosuppression given to treat irAEs related to checkpoint blockade. Indeed, several case reports have been published of opportunistic infections among patients with melanoma receiving the CTLA-4 inhibitor ipilimumab, including invasive aspergillosis, cytomegalovirus-induced hepatitis, and pneumocystis pneumonia (PCP) [19–21]. However, the full extent of infection among patients receiving these novel immunotherapies has not been determined.

Here we describe the spectrum of serious infections and associated risk factors among 740 melanoma patients treated with immune checkpoint inhibitors at Memorial Sloan Kettering Cancer Center (MSKCC).

METHODS

The study was performed at MSKCC (New York, New York), a 471-bed tertiary care cancer center with 19 000 admissions and 122 000 patient-days annually. We retrospectively reviewed the electronic medical records of all patients diagnosed with melanoma and treated with immune checkpoint (CTLA-4, PD-1, and/or PD-L1) blocking agents during a 4-year period from December 2010 to October 2014. Data collected included patient demographics, treatment modality and duration, prior cancer treatments, treatment of irAEs with any immunosuppressive drug, use of antimicrobial prophylaxis, and outcome. We specifically evaluated prior receipt of temozolomide due to its association with prolonged lymphopenia and opportunistic infections [22]. The study was approved by the MSKCC Institutional Review Board.

Infections were identified by reviewing patient laboratory data and imaging studies. For cases with microbiologic and/or radiologic findings suggestive of infection, we further reviewed the clinical medical records to confirm the presence of associated symptoms and ascertain the outcome. Cause of death was determined by agreement between the investigators.

Serious infection was defined as infection requiring hospitalization or parenteral antimicrobials. Serious infection related to immune checkpoint blockade was defined as serious infection occurring at any time from initiation of immune checkpoint blockade till 1 year after its discontinuation. Probable or proven

Received 28 March 2016; accepted 1 August 2016; published online 7 August 2016.

Correspondence: G. Redelman-Sidi, Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065 (redelmansidi@hotmail.com).

Clinical Infectious Diseases® 2016;63(11):1490–3

© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com. DOI: 10.1093/cid/ciw539

Table 1. Patient Characteristics and Risk Factors for Serious Infection

Characteristic (n = 740 Patients)	Overall	Serious Infection?		P Value	OR (95% CI)
		Yes (n = 54)	No (n = 686)		
Age, y, mean (range)	63 (4–93)	61.6 ± 2.0	63.0 ± 0.5	.47	
Male sex	469 (63)	40 (74)	430 (63)	.11	1.70 (.90–3.09)
Prior chemotherapy	229 (31)	20 (37)	209 (30)	.36	1.34 (.76–2.39)
Prior temozolomide	142 (19)	12 (22)	130 (19)	.59	1.22 (.64–2.36)
Corticosteroid use	339 (46)	46 (85)	293 (43)	<.0001	7.71 (3.71–16.18)
Infliximab use	54 (7)	13 (24)	41 (6)	<.0001	4.74 (2.27–9.45)

Treatment (n = 898 Treatment Courses)	Overall	Serious Infection?		P Value	OR (95% CI)
		Yes (n = 54)	Yes (n = 844)		
Ipilimumab	658 (73)	40 (74)	618 (73)	.99	1.05 (.55–1.90)
Nivolumab	52 (5.7)	1 (1.9)	51 (6)	.36	0.29 (.03–1.68)
Pembrolizumab	83 (9.2)	0 (0)	83 (9.8)	.0069	0 (0–63)
Ipilimumab + nivolumab	80 (8.9)	12 (22)	68 (8)	.0017	3.26 (1.70–6.27)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: CI, confidence interval; OR, odds ratio.

invasive fungal infection was defined according to published criteria [23]. Receipt of corticosteroids was defined as receipt of an average daily dose of at least 10 mg of prednisone or dose-equivalent corticosteroid for at least 10 days at any time from initiation of immune checkpoint blockade till 1 year after its discontinuation.

Statistical Analysis

Fisher exact test was used to analyze the association between development of infection and categorical variables (sex, use of corticosteroids, use of infliximab, prior temozolomide use, immune checkpoint blockade agent used). The Mann–Whitney test was employed to analyze the association between development of infection and continuous variables (age). A *P* value ≤.05 was considered significant.

RESULTS

During the 4-year study period, 740 patients received 898 courses of immune checkpoint blockade for melanoma at MSKCC. The mean patient age was 63 years; 469 (63%) were men. Two hundred twenty-nine patients (31%) had previously received cytotoxic chemotherapy, including 142 (19%) who had received temozolomide (Table 1).

Monotherapy with a checkpoint-blocking drug was given in 793 (88.3%) courses, including 658 (73.2%) with ipilimumab (CTLA-4 blocker), 52 (5.7%) with nivolumab (PD-1 blocker), and 83 (9.2%) with pembrolizumab (PD-1 blocker). Combination therapy was given in 105 (11.7%) courses, most commonly a combination of ipilimumab and nivolumab in 80 (8.9%), followed by nivolumab and lirilumab in 10 (1.1%). The average treatment course duration was 98 days (range, 1–1309 days).

Three hundred thirty-nine patients (46%) received corticosteroids, of whom 55 (16%) also received infliximab; 1 person was treated with infliximab alone. Other immunosuppressive medications administered included rituximab in 1 patient and mycophenolate-mofetil in 1 patient. The median daily corticosteroid dose (prednisone equivalent) was 40 mg, and the median duration of corticosteroid therapy was 60 days. PCP prophylaxis was given to 144 (42%) of those who received corticosteroids. No other antimicrobial prophylaxis was given.

Serious infection developed in 54 patients (7.3%). The average time from initiation of immune checkpoint blockade to

Table 2. Specific Infection Types

Infection Type	No. of Cases
Bacterial	46
Pneumonia	13
Intra-abdominal infection	7
Craniofacial infection	3
Bacterial bloodstream infection	13
<i>Clostridium difficile</i> -associated diarrhea	10
Fungal	6
Invasive pulmonary aspergillosis	2
Pneumocystis pneumonia	3
<i>Candida</i> bloodstream infection	1
Viral	5
Zoster (disseminated or facial)	3
CMV enterocolitis	1
EBV reactivation causing facial nerve paralysis	1
Parasitic	1
Strongyloides hyperinfection	1
Total ^a	58

Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus.

^a Total number of cases is more than the 54 patients who developed an infection, as some patients developed >1 infection.

development of infection was 135 days (range, 6–491 days). Infection occurred during the first 6 months after initiation of immune checkpoint blockade in 43 of the 54 patients (79.6%). The types of infections that occurred are shown in Table 2. Nine patients (17%) were deemed to have died as a consequence of the infection.

Risk Factors for Serious Infection

A comparison between the patients who developed serious infection and those who did not is shown in Table 1. Factors significantly associated with serious infection were use of corticosteroids (odds ratio [OR], 7.71; 95% confidence interval [CI], 3.71–16.18; $P < .0001$) and use of infliximab (OR, 4.74; 95% CI, 2.27–9.45; $P < .0001$). Use of a combination of ipilimumab and nivolumab was associated with increased risk of serious infection, whereas use of pembrolizumab was inversely associated with development of serious infection. Age, sex, and prior receipt of chemotherapy or temozolomide were not associated with development of serious infection.

DISCUSSION

In this study, we describe the occurrence of serious infections following immune checkpoint blockade in 740 patients with metastatic melanoma. This study is, to our knowledge, the first systematic review of infection among patients receiving immune checkpoint blockade for cancer therapy. We found that the overall incidence of serious infections in this population was 7.3%.

The major risk factor for development of serious infection among these patients was use of immunosuppressive agents, including corticosteroids and infliximab. The risk of serious infection was 13.5% in patients who received either corticosteroids or infliximab but only 2% in those who did not. Our study thus provides a clear definition of the population at risk for infection after immune checkpoint blockade.

We also found that patients receiving a combination of nivolumab and ipilimumab were more likely to have developed serious infection, whereas those who received pembrolizumab were protected. These associations are likely explained by the different incidence of irAEs with each of these treatment regimens. Other researchers have found that patients receiving a combination of nivolumab and ipilimumab had a higher risk for severe irAEs, compared with those receiving ipilimumab alone, and were more likely to require immunosuppressive therapy [2]. Indeed, only 5 of 83 (6%) pembrolizumab-treated patients in our study subsequently received corticosteroids, compared with 55 of 80 (69%) of those treated with nivolumab plus ipilimumab.

As we learn more from patients treated with these novel checkpoint-blocking antibodies, guidelines may be necessary to define the optimal management strategies for irAEs while also minimizing infectious complications. Many of the

infections identified in our study could potentially be prevented by use of antimicrobial prophylaxis, but the benefit of such prophylaxis needs to be weighed against the risk of adverse effects and promotion of antibiotic resistance. All 3 patients who developed PCP in our study had not received PCP prophylaxis. We would advocate that PCP prophylaxis be considered in all patients with irAEs who are expected to receive prednisone (or equivalent) for at least 4 weeks, in accordance with published guidelines [24]. The role of antiviral, antibacterial, or antifungal prophylaxis in these patients requires further study, particularly among those at the highest risk. At the minimum, clinicians caring for patients receiving corticosteroids or infliximab for treatment of irAEs should maintain high vigilance for occurrence of symptoms or signs suggestive of infection.

The major strength of our study is the large size of the cohort studied. However, our study also has 2 important limitations. First, the majority of patients in our cohort received ipilimumab alone, thus limiting our ability to generalize our conclusions to patients receiving other drug regimens. Second, our cohort consisted entirely of patients with melanoma. Future studies will be needed to determine whether our conclusions pertain to other populations treated with immune checkpoint blockade, such as patients with non-small-cell or renal-cell carcinoma.

In conclusion, patients with melanoma treated with immune checkpoint blockade have a low risk of developing serious infection, unless they also receive corticosteroids and/or TNF- α inhibitors to treat complications associated with immune checkpoint blockade. Future studies will need to address the best approach to optimize the management of irAEs while also preventing infectious complications among this emerging patient population.

Notes

Financial support. This work was supported by the National Cancer Institute at the National Institutes of Health (Cancer Center Support Grants P30 CA008748 and K08 CA184038 to G. R.-S.).

Potential conflicts of interest. All authors: No potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 2015; 373:23–34.
2. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015; 372:2006–17.
3. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; 372:320–30.
4. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med* 2015; 372:2521–32.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; 363:711–23.
6. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med* 2015; 372:311–9.
7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med* 2015; 373:1627–39.
8. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med* 2015; 373:123–35.

9. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* **2015**; 373:1803–13.
10. Callahan MK, Flaherty CR, Postow MA. Checkpoint blockade for the treatment of advanced melanoma. *Cancer Treat Res* **2016**; 167:231–50.
11. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* **2012**; 30:2691–7.
12. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. *JAMA Oncol* **2016**; 2:234–40.
13. De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. *Melanoma Res* **2015**; 25:321–7.
14. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. *J Clin Oncol* **2015**; 33:3193–8.
15. Postow MA. Managing immune checkpoint-blocking antibody side effects. *Am Soc Clin Oncol Educ Book* **2015**; 76–83.
16. Lazar-Molnar E, Chen B, Sweeney KA, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. *Proc Natl Acad Sci U S A* **2010**; 107:13402–7.
17. Seo SK, Jeong HY, Park SG, et al. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary *Listeria monocytogenes* infection. *Immunology* **2008**; 123:90–9.
18. Rowe JH, Johans TM, Ertelt JM, Way SS. PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated *Listeria monocytogenes*. *J Immunol* **2008**; 180:7553–7.
19. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA. Opportunistic infections in patients treated with immunotherapy for cancer. *J Immunother Cancer* **2014**; 2:19.
20. Uslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. *J Immunother* **2015**; 38:212–5.
21. Arriola E, Wheeler M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause pneumonia but spare antitumor immune control. *Oncoimmunology* **2015**; 4:e1040218.
22. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. *J Clin Oncol* **2004**; 22:610–6.
23. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* **2008**; 46:1813–21.
24. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. *J Natl Compr Canc Netw* **2012**; 10:1412–45.